ciforadenant   Click here for help

GtoPdb Ligand ID: 10190

Synonyms: CPI-444 | CPI444 | V-81444 | V81444
Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: Ciforadenant (CPI-444) is an orally active adenosine A2A receptor antagonist.
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 8
Hydrogen bond donors 1
Rotatable bonds 6
Topological polar surface area 127
Molecular weight 407.17
XLogP 0.65
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES Nc1nc(c2ccc(o2)C)c2c(n1)n(nn2)Cc1cccc(n1)COC1COCC1
Isomeric SMILES Nc1nc(c2ccc(o2)C)c2c(n1)n(nn2)Cc1cccc(n1)CO[C@@H]1COCC1
InChI InChI=1S/C20H21N7O3/c1-12-5-6-16(30-12)17-18-19(24-20(21)23-17)27(26-25-18)9-13-3-2-4-14(22-13)10-29-15-7-8-28-11-15/h2-6,15H,7-11H2,1H3,(H2,21,23,24)/t15-/m0/s1
No information available.
Summary of Clinical Use Click here for help
Ciforadenant (CPI-444) is being evaluated for immuno-oncology potential in combination with anti-PD-L1 checkpoint inhibitor atezolizumab (Phase 1/1b NCT02655822). Preclinical studies indicate that ciforadenant enhances the antitumour responses to both anti-PD-L1- and anti-CTLA-4-induced checkpoint inhibition in vivo [2].
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT02655822 Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers Phase 1 Interventional Corvus Pharmaceuticals, Inc.